| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BYK; Brt; Dtk; RSE; Sky; Tif |
| Entrez GeneID | 7301 |
| clone | 10E11 |
| WB Predicted band size | 96.9kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant extracellular fragment of human TYRO3 fused with hIgGFc tag expressed in HEK293 cell line. |
| Formulation | Ascitic fluid containing 0.03% sodium azide. |
+ +
以下是关于TYRO3抗体的3篇代表性文献示例(注：文献标题及作者为虚拟，仅用于示例)：
1. **文献名称**：*"TYRO3 receptor inhibition using monoclonal antibodies suppresses metastasis in ovarian cancer models"*
**作者**：Chen L, et al.
**摘要**：研究开发了靶向TYRO3的单克隆抗体，证实其可通过阻断TYRO3与配体Gas6的结合，抑制卵巢癌细胞迁移和侵袭，并减少体内转移灶形成。
2. **文献名称**：*"Antibody-mediated targeting of TYRO3 enhances anti-PD-1 therapy efficacy in hepatocellular carcinoma"*
**作者**：Kim S, et al.
**摘要**：该文献报道了TYRO3抗体与PD-1抑制剂联用可协同激活肿瘤微环境中CD8+ T细胞，抑制肝癌生长，揭示了TYRO3作为免疫治疗联合靶点的潜力。
3. **文献名称**：*"TYRO3 regulates apoptotic resistance in glioblastoma via antibody-blockable kinase signaling"*
**作者**：Garcia-Rojas A, et al.
**摘要**：通过抗体验证TYRO3在胶质母细胞瘤中的促存活作用，其抗体可诱导肿瘤细胞凋亡并增强放疗敏感性，机制涉及ERK信号通路抑制。
4. **文献名称**：*"Structural characterization of a TYRO3-neutralizing antibody and its epitope mapping"*
**作者**：Tanaka H, et al.
**摘要**：解析了TYRO3中和抗体的结构，确定其结合表位位于TYRO3胞外免疫球蛋白样结构域，为优化抗体药物设计提供依据。
(注：以上文献为示例，实际引用需查询真实数据库如PubMed。)
TYRO3. a member of the TAM receptor tyrosine kinase family (including AXL and MER), plays critical roles in cellular homeostasis, immune regulation, and oncogenesis. Structurally, it consists of an extracellular ligand-binding domain, a transmembrane region, and an intracellular kinase domain. TYRO3 is activated by ligands like Gas6 and Protein S, leading to receptor dimerization and phosphorylation, which triggers downstream signaling pathways (e.g., PI3K/AKT, MAPK/ERK) involved in cell survival, proliferation, and migration. It is highly expressed in immune cells, neurons, and reproductive tissues, where it modulates processes such as phagocytosis, inflammation, and synaptic plasticity.
TYRO3 antibodies are tools used to study its expression, activation mechanisms, and pathological roles. Dysregulated TYRO3 signaling is linked to cancer progression (e.g., metastasis, drug resistance), autoimmune diseases, and viral infections (e.g., Zika, dengue), making it a therapeutic target. Antibodies targeting TYRO3 (monoclonal or polyclonal) can block ligand-receptor interactions, inhibit kinase activity, or promote receptor degradation. In preclinical studies, anti-TYRO3 antibodies have shown potential in suppressing tumor growth and enhancing immune responses. However, challenges remain in achieving specificity due to structural homology among TAM receptors. Research continues to optimize antibody design for clinical applications, including cancer immunotherapy and treatment of inflammatory disorders.
×
